Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ALX Oncology Holdings Inc ALXO

Healthcare Biotechnology
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALXO)

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire 11 days ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

GlobeNewswire 12 days ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

GlobeNewswire February 27, 2025

ALX Oncology to Host Virtual R&D Day on March 5, 2025

GlobeNewswire February 18, 2025

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

GlobeNewswire January 23, 2025

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

GlobeNewswire January 22, 2025

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

GlobeNewswire January 22, 2025

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

GlobeNewswire January 21, 2025

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2025
View More News ››

Opinion & Analysis (NDAQ:ALXO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALXO)

ALX Oncology to Host Virtual R&D Day on March 5, 2025

BREAKING NEWS: $ALXO ALX Oncology to Host Virtual R&D Day on March 5, 2025SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE...
whytestocks - February 18, 2025
View more Bullboard ››

Visionstate Corp.

Visionstate Corp.

Visionstate Corp.is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »